[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352352-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352352-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","optimizing-anti-pi3k-and-anti-lag-3-immunotherapy-dosing-regimens-in-a-mouse-model-of-triple-negative-breast-cancer-improves-outcome-by-removing-treatment-related-adverse-events","Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events","","Current immunotherapy regimens often fail because T-cell responses are insufficient and immune-related adverse events (irAEs) cause treatment discontinuation; combination strategies can further increase irAE risk. In preclinical triple-negative breast cancer, dual PI3Kδ inhibition plus anti-LAG-3 antibody targeting shows strong tumor control but poor tolerability with substantial toxicity. This study explores dosing and delivery strategies to sustain antitumor immunity while mitigating toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/optimizing-anti-pi3k-and-anti-lag-3-immunotherapy-dosing-regimens-in-a-mouse-model-of-triple-negative-breast-cancer-improves-outcome-by-removing-treatment-related-adverse-events/352352/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/optimizing-anti-pi3k-and-anti-lag-3-immunotherapy-dosing-regimens-in-a-mouse-model-of-triple-negative-breast-cancer-improves-outcome-by-removing-treatment-related-adverse-events/352352.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are current immunotherapy regimens insufficient for some cancer patients?","Question",{"text":63,"@type":64},"They often fail due to an insufficient T cell response and/or immune-related adverse events (irAEs) that lead to treatment discontinuation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What combination strategy was tested in the triple-negative breast cancer mouse model?",{"text":68,"@type":64},"Combination immunotherapies using a PI3Kδ inhibitor (PI-3065) together with LAG-3 targeting treatments were evaluated to optimize tumor control while limiting irAE.",{"name":70,"@type":61,"acceptedAnswer":71},"Which dosing and delivery approach reduced toxicity while maintaining tumor control?",{"text":72,"@type":64},"Intermittent dosing of the PI3Kδ inhibitor combined with anti-LAG-3 treatment prevented initial irAE development and enabled excellent tumor control without systemic adverse effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352352,1790465098,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Open access Original research  \n Optimizing anti-PI3Kδ and anti-LAG-3  \nimmunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events  \nSarah Nicol Lauder  ,1 Ana Pires,1 Michelle Somerville,1 Lorenzo Capitani,1 Kathryn Smart,1 James Geary,1 Emily M Mills,1 Bart Vanhaesebroeck,2 Andrew Godkin,1 Awen Gallimore  1  \nTo cite: Lauder SN, Pires A, Somerville M, et al. Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events. Journal for ImmunoTherapy of Cancer 2026;14:e012157 . doi:10 . 1136/ jitc-2025-012157  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012157](jitc-2025-012157)) .  \nSNL and AP contributed equally. Accepted 10 January 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group. 1Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK 2UCL Cancer Institute, University College London, London, UK  \nCorrespondence to  \nDr Sarah Nicol Lauder; [LauderSN@cardiff.ac.uk](LauderSN@cardiff.ac.uk)  \nABSTRACT  \nBackground Current immunotherapy regimens most often fail due to an insufficient T cell response and/or immune-related adverse events (irAEs) which lead to treatment discontinuation. Additionally, many cancers likely require combination immunotherapies which may further increase irAE. This is exemplified in our preclinical models of dual targeting of regulatory T cells with a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor and antibodies to LAG-3. Indeed, while this approach in preclinical models of triple-negative breast cancer shows excellent tumor control, treatment is poorly tolerated and results in significant toxicity. Given the emerging relevance of these targets in human breast cancer, we explored strategies to sustain tumor immunity while mitigating toxicity using these therapeutic modalities.  \nMethods Different approaches to combination immunotherapies employing a PI3Kδ inhibitor (PI-3065) with LAG-3 targeting treatments were tested in a mouse model of triple-negative breast cancer to optimize tumor control while limiting irAE.  \nResults Systemic targeting of the LAG-3 ligand FGL1 did not provide additional anticancer benefit but markedly worsened irAE. Localized delivery of anti-LAG-3 antibodies to the tumor microenvironment promoted tumor control while reducing the overall number of animals experiencing severe irAE compared with those receiving systemic LAG-3 blockade. However, intermittent dosing of the PI3Kδ inhibitor in combination with anti-LAG-3 treatment prevented the initial development of irAE and enabled excellent tumor control without systemic adverse effects. Conclusions Our data demonstrated that refining immunotherapy delivery approaches can improve tolerability that ultimately transforms treatment success.  \nINTRODUCTION  \nSince the first immune checkpoint inhibitor (ICI) was licensed in 2011, these novel immunotherapies have broadened treatment options for cancer with a proportion of patients achieving “miraculous” cures of  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Previous studies have demonstrated that PI-3065, a small molecule inhibitor of the PI3Kδ signaling pathway, in combination with anti-LAG-3 antibody therapy can promote robust tumor control in preclinical models. This combination approach however has been reported to drive the development of immunerelated adverse events (irAEs) .\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study in a preclinical model of triple-negative breast cancer (TNBC), demonstrated that intermittent dosing of PI-3065, combined with systemic inhibition of LAG-3 signaling enables robust tumor regression and prevents the development of treatment-","cbCaiuFG0WD2nZgX","https://ap.wps.com/l/cbCaiuFG0WD2nZgX","pdf",11601141,15,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Introduction\n## What is already known on this topic\n## What this study adds\n## How this study might affect research, practice or policy","[{\"question\":\"Why are current immunotherapy regimens insufficient for some cancer patients?\",\"answer\":\"They often fail due to an insufficient T cell response and/or immune-related adverse events (irAEs) that lead to treatment discontinuation.\"},{\"question\":\"What combination strategy was tested in the triple-negative breast cancer mouse model?\",\"answer\":\"Combination immunotherapies using a PI3Kδ inhibitor (PI-3065) together with LAG-3 targeting treatments were evaluated to optimize tumor control while limiting irAE.\"},{\"question\":\"Which dosing and delivery approach reduced toxicity while maintaining tumor control?\",\"answer\":\"Intermittent dosing of the PI3Kδ inhibitor combined with anti-LAG-3 treatment prevented initial irAE development and enabled excellent tumor control without systemic adverse effects.\"}]","Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events | PDF",1790099129,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c78f4fad8a45e631bbe7946fbeda761.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b96230388972f46fa1b427bbca7ad04.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c56c2e614cdce3b4526691a1458cf362.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2890c19c86aaf4d5e2aa32f567d6506.webp",980,1306]